Skip to main content

Advertisement

SpringerLink
Log in

HBV plus HCV, HCV plus HIV, HBV plus HIV

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Coinfection of hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV is common due to shared modes of transmission. These coinfections accelerate the course of chronic liver disease and facilitate progression to cirrhosis and hepatocellular carcinoma. The viral interactions between these viruses are complex, and their treatment may be challenging for clinicians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Detels R, Munoz A, McFarlane G: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280:1497–1503.

    Article  PubMed  CAS  Google Scholar 

  2. National Institute of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Hepatology 2002, 36(5):S3-S20.

    Article  Google Scholar 

  3. Sherman KE, Rouster SD, Chung RT, et al.: Hepatitis C Virus prevalence among patients infected with human Immunode ficiency virus: a cross sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831–837. This is a well-designed cross-sectional analysis evaluating the epidemiology of HIV/HCV coinfection.

    Article  PubMed  Google Scholar 

  4. Gerlach JT, Diepolder HM, Jung M-C, et al.: Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C. Gastroenterology 1999, 117:933–941.

    Article  PubMed  CAS  Google Scholar 

  5. John M, Flexman J, French MA: Hepatitis C virus associated hepatitis following treatment of HIV infected patients with protease inhibitors: an immune restoration disease? AIDS 1998, 12:2289–2293.

    Article  PubMed  CAS  Google Scholar 

  6. Woitas RP, Rockstroh JK, Beier I, et al.: Antigen specific cytokine response to hepatitis C virus core epitopes in HIV/ hepatitis c virus coinfected patients. AIDS 1999, 13:1313–1322.

    Article  PubMed  CAS  Google Scholar 

  7. Cribier B, Rey D, Schmitt C, et al.: High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995, 9:1131–1136.

    Article  PubMed  CAS  Google Scholar 

  8. Bonacini M, Govindarajan S, Blatt LM, et al.: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999, 6:203–208.

    Article  PubMed  CAS  Google Scholar 

  9. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus infection and hepatitis C virus coinfected patients. Hepatology 1999, 30:1054–1058.

    Article  PubMed  CAS  Google Scholar 

  10. Macias J, Castellano V, Merchante N, et al.: Effect of antiretroviral drugs on liver fibrosis in HIV infected patients with chronic hepatitis C: harmful effect of nevirapine. AIDS 2004, 18:767–774.

    Article  PubMed  CAS  Google Scholar 

  11. Mehta SH, Thomas DL, Torbenson M, et al.: The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005, 41:123–131.

    Article  PubMed  Google Scholar 

  12. Kelleher TB, Mehta SH, Bhaskar R, et al.: Prediction of hepatic fibrosis in HIV/HCV coinfection using serum fibrosis markers: The SHASTA index. J Hepatol 2005, 43:78–84.

    Article  PubMed  Google Scholar 

  13. Sulkowski MS, Mehta HS, Torbenson M, et al.: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005, 19:585–592.

    Article  PubMed  Google Scholar 

  14. Puoti M, Bruno R, Soriano V, et al.: Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004, 18:2285–2293.

    Article  PubMed  Google Scholar 

  15. Bica I, McGovern B, Dhar R, et al.: Increasing mortality in end stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32:492–497.

    Article  PubMed  CAS  Google Scholar 

  16. Monto A, Dove LM, Seal KH, et al.: HIV-HCV Coinfected patients followed prospectively for a mean of 4.2 years, have similar rates of death or cirrhosis compared to HCV mono-infected patients. Hepatology 2004, 40(Suppl 1):1212A.

    Google Scholar 

  17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV infected patients. N Engl J Med 2004, 351:438–450. This is the largest clinical study analyzing different anti-HCV treatments in HIV/HCV coinfection and demonstrating a role of EVR and stopping treatment early in absence of viral clearance.

    Article  PubMed  CAS  Google Scholar 

  18. ChungRT, Anderson J, Volberding P, et al.: Peginterferon alfa -2a plus ribavirin versus interferon alfa 2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med 2004, 351:451–499. This randomized clinical trial compares PEG-IFN weekly to standard IFN thrice a week. The study also demonstrates a possible role of maintenance therapy in coinfected patients.

    Article  PubMed  CAS  Google Scholar 

  19. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b versus standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839–2848. This study used a higher dose of ribavirin and showed SVR of 38% in genotype 1. This is higher than findings reported in other studies, suggesting that HIV/HCV coinfected patients may have a higher SVR with a higher dose weight-based ribavirin regime.

    Article  PubMed  CAS  Google Scholar 

  20. Laguno M, Murillas J, Blanco JL, et al.: Peginterferon alpha 2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 2004, 18:F27-F36.

    Article  PubMed  CAS  Google Scholar 

  21. Dieterich DT, Spivak JL: Hematological disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003, 37:533–541.

    Article  PubMed  CAS  Google Scholar 

  22. Dieterich D, Sulkowski M, Bini E, itet al.: Epoetin-alfa administered once weekly improves anemia in HIV/HCV coinfected patients treated with interferon/ribavirin therapy: a prospective, randomized study. Presented at the 11th conference on Retroviruses and Opportunistic Infections (A824), San Francisco, CA, February 2004.

  23. Brau N, Rodriguez-Torres M, Prokupek D, et al.: Treatment of chronic hepatitis C in HIV/HCV coinfection with interferon alpha 2b full course vs. 16 week delayed ribavirin. Hepatology 2004, 39:989–998.

    Article  PubMed  CAS  Google Scholar 

  24. Sulkowski MS, Felizarta F, Smith C, et al.: daily vs. 3 times weekly interferon alfa 2b plus ribavirin for the treatment of hepatitis C infection in HIV infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004, 35:464–472.

    Article  PubMed  CAS  Google Scholar 

  25. Kakuda TN, Brinkman K: Mitochondrial toxic effects and ribavirin. Lancet 2001, 357:1802–1803.

    Article  PubMed  CAS  Google Scholar 

  26. Taylor LE, Costello T, Alt E, et al.: Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals. AIDS 2002, 16:1700–1701.

    Article  PubMed  Google Scholar 

  27. National Institute of Health Consensus Development Conference Statement. Management of Hepatitis C: 2002. Hepatology 2002, 36(5):S3-S20.

    Article  Google Scholar 

  28. Soriano V, Pouti M, Sulkowski M, et al.: Care of patients with hepatitis C and HIV coinfection. AIDS 2004, 18:1–12.

    Article  PubMed  Google Scholar 

  29. Thio C, Seaberg E, Skolasky R, et al.: HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter AIDS Cohort Study (MACS), Lancet 2002, 360:1921–1926.

    Article  PubMed  Google Scholar 

  30. Kellerman S, Hanson D, McNaghten A, et al.: Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects, J Infect Dis 2003, 188:571–577.

    Article  PubMed  Google Scholar 

  31. Sheng WH, Chen MY, Hsieh SM, et al.: Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004, 38:1471–1477.

    Article  PubMed  Google Scholar 

  32. Rehermann B: Immune responses in hepatitis B virus infection. Semin Liver Dis 2003, 23:21–37.

    Article  PubMed  CAS  Google Scholar 

  33. Bodsworth NJ, Cooper DA, Donovan B: The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163:1138–1140.

    PubMed  CAS  Google Scholar 

  34. Rector W, Govindarajan S, Horsburgh C, et al.: Hepatic inflammation, hepatitis B replication, and cellular immune function in homosexual males with chronic hepatitis B and antibody to HIV. Am J Gastroenterol 1988, 83:262–266.

    PubMed  Google Scholar 

  35. Hollinger FB: Hepatitis B virus. In Virology, edn 3. Edited by Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven Publishers; 1997:2738–2808.

    Google Scholar 

  36. Soriano V, Puoti M, Bonacini M, et al.: Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an international HBV/HIV Panel, AIDS 2005, 19:221–240.

    Article  PubMed  Google Scholar 

  37. Allen ML, Deslauriers M, Andrews CW, et al.: Lamivudine Clinical Investigation Group. Identification and characterization of mutations in hepatitis b virus resistant to lamivudine. Hepatology 1998, 27:1670–1677.

    Article  PubMed  CAS  Google Scholar 

  38. Thibault V, Benhamou Y, Seguret C, et al.: Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999, 37:3013–3016.

    PubMed  CAS  Google Scholar 

  39. Bessesen M, Ives D, Condreay L, et al.: Chronic active hepatitis B exacerbations in HIV-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 285:1032–1035.

    Google Scholar 

  40. Gish RG, Leung NW, Wright TL, et al.: Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002, 46:1734–1740.

    Article  PubMed  CAS  Google Scholar 

  41. Lau GK, Tsiang M, Hou J, et al.: Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000, 32:394–399.

    Article  PubMed  CAS  Google Scholar 

  42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800–807.

    Article  PubMed  CAS  Google Scholar 

  43. Marcellin P, Chang TT, Lim SG, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808–816.

    Article  PubMed  CAS  Google Scholar 

  44. Peters MG, Hann HW, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91–101.

    Article  PubMed  CAS  Google Scholar 

  45. Benhamou Y, Bochet M, Thibault V: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label study. Lancet 2001, 358:718–723.

    Article  PubMed  CAS  Google Scholar 

  46. Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV DNA polymerase. Gastroenterology 2003, 125:292–297.

    Article  PubMed  Google Scholar 

  47. Nunez M, Perez-Olmeda M, Diaz B, et al.: Activity of tenofovir on hepatitis B virus replication in HIV-coinfected patients failing or partially responding to lamivudine. AIDS 2002, 16:2352–2354.

    Article  PubMed  CAS  Google Scholar 

  48. Peters M, Anderson J, Lynch P, et al.: Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are coinfected with HIV: results of ACTG A5127. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22–25, 2005.

  49. Saumoy M, Vidal F, Peraire J, et al.: Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004, 18:1741–1742.

    Article  PubMed  CAS  Google Scholar 

  50. Van Bommel F, Wunsche T, Mauss S, et al.: Comparison of adefovir and tenofovir in the treatment of lamivudineresistant hepatitis B virus infection. Hepatology 2004, 40:1421–1425. This study compared adefovir with tenofovir in HBV-monoinfected patients. The tenofovir group had a significantly earlier response to treatment and a greater mean HBV DNA log10 drop (5.5 vs 2.8 log) at week 48 than did the adefovir group. There was also a better serologic response in the tenofovir group, with 11 of the patients seroconverting to anti-HBe, and five of these patients had HBsAg loss.

    Article  PubMed  CAS  Google Scholar 

  51. Callens S, De Roo A, Colebunders R: Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect 2003, 47:262–263.

    Article  PubMed  Google Scholar 

  52. Ristig MB, Crippin J, Aberg JA, et al.: Tenofivir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B viruscoinfected individuals for whom interferon-a and lamivudine therapy have failed. J Infect Dis 2002, 186:1844–1847.

    Article  PubMed  CAS  Google Scholar 

  53. Levine S, Hernandez D, Yamanaka G, et al.: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46:2525–2532.

    Article  PubMed  CAS  Google Scholar 

  54. Tenney DJ, Levine SM, Rose RE, et al.: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48:3498–3507.

    Article  PubMed  CAS  Google Scholar 

  55. Soriano V, Puoti M, Bonacini M, et al.: Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an international HBV/HIV panel. AIDS 2005, 19:221–240.

    Article  PubMed  Google Scholar 

  56. Pessoa W, Gazzard B, Huang A, et al.: Entecavir in HIV/HBV-co-infected patients: safety and efficacy in a phase II study (ETV-038). Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005 (abstract 123).

  57. Weltman MD, Brotodihardjo A, Crewe ER, et al.: Coinfection with hepatitis B and C or B, and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995, 2:39–45.

    PubMed  CAS  Google Scholar 

  58. Sagnelli E, Pasquale N, Coppola N, et al.: Influence of chronic coinfection with hepatitis B and C virus on liver histology. Infection 2003, 32:144–148.

    Article  Google Scholar 

  59. Kew MC, Yu MC, Kedda MA, et al.: The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997, 112:184–187.

    Article  PubMed  CAS  Google Scholar 

  60. Cacciola I, Pollicino T, Squadrito G, et al.: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341:22–26.

    Article  PubMed  CAS  Google Scholar 

  61. Sagnelli E, Coppola N, Scolastico C, et al.: HCV genotype and silent HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001, 64:350–355.

    Article  PubMed  CAS  Google Scholar 

  62. Villa E, Grottola A, Buttafoco P, et al.: High doses of á-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001, 96:2973–2977.

    PubMed  CAS  Google Scholar 

  63. Zignego A, Fontana R, Puliti S, et al.: Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997, 142:535–544.

    Article  PubMed  CAS  Google Scholar 

  64. Fukuda R, Ishimura N, Hamamoto S, et al.: Coinfection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in liver. J Med Virol 2001, 63:220–227.

    Article  PubMed  CAS  Google Scholar 

  65. Tsai SL, Liaw YF, Yeh CT, et al.: Cellular immune responses in patients with dual infection of hepatitis B and C viruses: dominant role of hepatitis C virus. Hepatology 1995, 21:908–912.

    PubMed  CAS  Google Scholar 

  66. Wang YM, Ng WC, Lo SK: Suppression of hepatitis C virus by hepatitis B virus in coinfected patients at the national university hospital of Singapore. J Gastroenterology 1999:481–485.

  67. Koike K, Yasuda K, Yotsuyanagi H, et al.: Dominant replication of either virus in dual infection with hepatic viruses B and C. J Med Virol 1995, 45:236–239.

    Article  PubMed  CAS  Google Scholar 

  68. Keeffe EB, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004, 2:87–106.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Liver Diseases, Department of Medicine, Mount Sinai Medical Center, 5 East 98th Street, 11th Floor, 10029, New York, NY, USA

    Douglas T. Dieterich MD

Authors
  1. James S. Park MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neeraj Saraf MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas T. Dieterich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas T. Dieterich MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, J.S., Saraf, N. & Dieterich, D.T. HBV plus HCV, HCV plus HIV, HBV plus HIV. Curr Gastroenterol Rep 8, 67–74 (2006). https://doi.org/10.1007/s11894-006-0066-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-006-0066-9

Keywords

Search

Navigation